The susceptibility of mice to infection with MM virus is markedly increased after treatment with the sex hormone estrone. Studies were undertaken to determine if either suppression of production or interference with the action of interferon was involved in this phenomenon. The protection of mice against MM virus infection by several interferon-inducing agents was partially impeded by estrone treatment either 24 hr before or 24 hr after the administration of the inducing agent. The titers of circulating interferon induced by each of the agents were lower in estrone-pretreated animals than in untreated controls. The protection of mice by exogenous L cell interferon was blocked only when the hormone was given prior to the interferon. It is concluded that the adverse activity of estrone is related to its ability to interfere with the action of interferon.
The susceptibility of mice to infection with MM virus was previously shown to be markedly increased after treatment with the sex hormone estrone (6) . Estrone appeared to antagonize a mechanism of natural resistance. Previous data have demonstrated that in tissue culture MM virus is a potent inducer of interferon and is sensitive to its action (5) . We postulated that inoculation of normal mice with a small dose of MM virus leads to the production of interferon which limits the infection and protects many of the animals from fatal illness. Thus, the viral infection-enhancing (VIE) activity of estrone might result from reduced interferon production as observed in cortisone-treated mice (12) , or interferon may be produced but may be unable to function normally in hormone-treated mice. The present study was undertaken to examine the effect of estrone on the production and action of interferon in mice and on the antiviral protection of mice by inducers of interferon.
MATERIALS AND METHODS
Virus, medium, and cells. A stock suspension of MM virus containing 2.7 X 108 plaque-forming units (PFU) per ml was prepared and titrated in L cell monolayer cultures as described previously (5) . L cells were grown in Blake bottles with a modified Eagles' medium (3) containing Hanks balanced salt solution (HBS), twice the prescribed concentration of vitamins and amino acids, and 10%0 fetal calf serum.
Mice were inoculated intraperitoneally with approximately 30 PFU in 0.2 ml of HBS, and the number of deaths was recorded daily for a period of 14 days.
Animals. Male Swiss albino mice weighing 14 to 20 g were purchased from Simonsen Laboratories, Gillroy, Calif., or Southern Animal Farms, Prattville, Ala.
Steroid. Two different preparations of estrone in aqueous solution were purchased from Bioline Laboratories and used in these studies. Each ml of one (preparation A) contained 5 mg of estrone, 10%
propylene glycol, 0.9% sodium chloride, 0.025% sodium carboxymethyl cellulose, 0.02% polyethylene glycol, 0.05% polysorbate, and 0.01% thimersol, whereas each milliliter of the other (preparation B) contained 5 mg of estrone, 0.9% sodium chloride, 0.5% procaine HCI, and 0.01% thimersol. A 2-mg dose of the hormone in a volume of 0.4 ml was injected intraperitoneally into mice.
Interferon inducers. Statolon was provided by W. J. Kleinschmidt (Lilly Research Laboratories, Indianapolis, Ind.) and was given at a dose of 8 mg per mouse. Pyran copolymer (divinyl ether-maleic anhydride copolymer) was obtained from Hercules Inc., Wilmington, Del., and was given at a dose of 200 ,ug per mouse. Newcastle disease virus (NDV), obtained from B. P. Sagik, University of Texas, Austin, Tex., was propagated in chick embryos and was used at a dose of 4 X 107 PFU in a volume of 0.2 ml per mouse. Endotoxin (Escherichia coli 0:128:B12 lipopolysaccharide B) was purchased from Difco Laboratories, Inc., and was given at a dose of 100,ug per mouse. Poly I poly C (poly I: C) (Microbiological Associates Inc., Bethesda, Md.) was given at a dose of 100 Mg/mouse. All of the inducers were administered intraperitoneally except NDV which was given intravenously.
Interferon assay. Serum samples were collected and exposed to a Westinghouse G8T15 ultraviolet lamp at a distance of 12 cm for 5 min to eliminate interference due to viral particles (5 (Table 1) show that the interferon inducers effectively protected the mice against lethal infection (P < 0.001 for each inducer). Pretreatment with estrone, however, resulted in increased mortality in all inducer-treated groups. Mortality in mice protected with endotoxin or pyran was no longer significantly different from the [HBS-HBS]-treated control group, whereas that in statolonor NDV-protected mice was lower than control (P < 0.005 and < 0.05, respectively). Comparison of the mortalities in the estrone-treated groups to the [estrone-HBS]-treated group revealed that each inducer still manifested a significant degree of protection (P < 0.001 in each instance). It was also found (data not shown) that after hormone treatment the mortality in endotoxin-protected mice was greater (P < 0.025) than that in either of the other inducer-protected groups. The interferon data show that in each instance estrone inhibited the amount of circulating interferon at the times tested. Interferon induced by endotoxin, NDV, or pyran was reduced by about two-thirds, whereas that induced by statolon was reduced by about one-third. In the case of endotoxin or statolon, there appears to be a correlation between the relative decrease in the amount of interferon produced and the relative increase in susceptibility to infection in estrone-treated mice. These two parameters are not as closely correlated in mice given NDV or pyran, although the hormone did cause significant increases in mortality and decreases in interferon production. These data show that estrone interfered with the protective action of the interferon inducers tested and suggest that one of the possible mechanisms involved may be an interference by the hormone with interferon production.
We considered the possibility that residual estrone in the serum samples might interfere in the assay of interferon, thereby causing the apparent decrease in interferon titers. Interferon was prepared in L cells and assayed by a PR50 technique (5). The interferon titer was 3,000 units whether the preparation was diluted in medium containing 70 ,ug of estrone per ml or in normal medium. These results were similar to those of Rienicke who reported that, although estradiol inhibited interferon production by chick embryo fibroblast (CEF) cultures (11), it did not inhibit interferon action in the CEF system (10). We concluded that in the above experiment, the reduced interferon titers were the result of reduced interferon production and not due to an inhibition with the action of interferon in the assay system.
Effect of estrone on the mortality of mice pretreated with interferon inducers. The previous experiment suggested that the VIE activity of estrone might be the result of its ability to suppress interferon production. I It was previously demonstrated (6) that the viral infection-enhancing activity of estrone was essentially the same whether it was administered 48 or 24 hr before virus challenge. 24 hr after estrone treatment. Each group contained approximately 40 mice. All animals were challenged with MM virus 24 hr later. The results (Table 3) show that the interferon effectively protected the mice against lethal infection. This protection was inhibited by estrone only when the hormone was given before the interferon (P < 0.001). These data are consistent with the hypothesis that estrone interferes with the action of interferon.
DISCUSSION
Estrone administration was previously found to increase the susceptibility of mice to lethal infection with MM virus (6) . It was also reported that this capability which was termed VIE activity was primarily due to the hormone and not to compounds in the diluent. In the present study, two lots of estrone containing different diluents had similar VIE activity (Table 1 and 2). The data presented in Table 1 demonstrate that the protection evoked by several interferon-inducing agents (statolon, endotoxin, NDV, pyran) can be partially blocked by pretreating the animals with estrone and that such treatment resulted in lower levels of circulating interferon. These observations suggested that estrone increased the susceptibility to infection by antagonizing the production of interferons in mice. Similarly, corticosteroid hormones have been reported to increase the susceptibility of animals to viral diseases (7, 14) and to suppress the induction of interferon by NDV in mice (12) . However, the data reveal that despite the presence of relatively high levels (260 or 680 units) of statolon-or NDV-induced interferon after estrone treatment, the mice were more susceptible to infection than control animals with much lower endotoxin-or pyraninduced interferon titers (25 or 30 units). This observation suggested that circulating interferon titers might not reflect the degree of protection and that the reduced interferon titers could not account (or were not a major factor) for the increased susceptibility to infection.
The possibility that estrone interfered with the ability of interferon to function was investigated by administering the hormone after endogenous interferon had already been produced and by testing its effect on protection induced by exogenous interferon. The data (Tables 2 and 3) show that estrone adversely affected the antiviral resistance of mice conferred by statolon, poly I:C, NDV, or endotoxin even though the hormone was given after maximal circulating interferon levels had been reached. Furthermore, treatment of mice with estrone decreased the ability of exogenous interferon given 24 hr later to protect the animals, whereas administration of the hormone 24 hr after interferon treatment did not alter the protective action of the interferon. Apparently, once the interferon-induced virus-resistant state had been established, subsequent treatment with estrone did not cancel that resistance. The interference with viral protection seen in Table 2 could be explained by assuming that the antiviral function of the induced interferon had not yet been fully expressed at the time of hormone treatment. These data are in agreement with the hypothesis that a factor other than decreased interferon production is involved in the VIE activity of estrone and that the factor may involve interference with the host response to existing interferon.
The problem under study is complex, and the available information does not allow us to fully explain the VIE activity of estrone and other steroids. The data presented, however, strongly suggest that interference with the action of inter-VOL. 3, 1971 feron might play an important role in this phenomenon.
